Aligos Therapeutics, Inc. (NasdaqCM: ALGS)
Health Care · Biotechnology · US
$6.67
-3.19% today · -34.7% 1Y
Aligos Therapeutics, Inc. (NasdaqCM: ALGS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $41.65M and employs 82 people.
Over the last twelve months the share price has lost 34.7%, trading between 3.98 and 13.69.
Tweenvest scores Aligos Therapeutics, Inc. across four factors: quality 26/100, value 66/100. Its strongest factor is value.
ALGS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $41.65M
- Revenue (TTM)
- $31.52M
- P/E
- —
- EPS
- -7.31
- Dividend yield
- —
- Beta (5Y)
- 2.28
- 52-week high
- $13.69
- 52-week low
- $3.98
- Avg volume (3M)
- —
- Shares outstanding
- 6.24M
- Employees
- 82
- Next earnings
- —
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
- Founded
- 2018
- Listed since
- Oct 16, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.